TLX

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

Retrieved on: 
수요일, 9월 21, 2022
Kepler, Headache, ASX, Safety, Radiation, Brain, FDA, Food, Glioblastoma, Diarrhea, Australian Securities Exchange, Hiccup, Principal, MTR, LinkedIn, Population, Company, TLX, TGA, Degenerative disease, GBM, Survival, Patient, Platelet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Insomnia, Gallium, Cerebral edema, Diagnosis, Neoplasm, Fatigue, Lymphocyte, Swelling, EBRT, Pharmaceutical industry, Medical imaging, Telix

The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM.

Key Points: 
  • The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM.
  • Final data up to the completion of the post-study follow-up period confirms the study has met its primary objective, demonstrating the safety and tolerability profile of TLX101 at the dosing range tested.
  • The study also delivered encouraging preliminary efficacy data for further evaluation, demonstrating a median overall survival (OS) of 13 months from the initiation of treatment in the recurring setting, or 23 months from initial diagnosis.
  • We can reconfirm that TLX101 has demonstrated safety and tolerability profile and encouraging early efficacy data.

Standard Motor Products Introduces Over 300 New Part Numbers

Retrieved on: 
목요일, 8월 25, 2022
Shift, Transfer, Odyssey, Completeness, Lincoln, Turbocharger, Honda, Subaru Outback, Advanced driver-assistance systems, Collision, Acura, Standard, Buick Encore, Nissan Leaf, SMP, MKX, Service King Collision Repair, Temperature, Toyota, Heater core, Hyundai, Mercedes-Benz B-Class, Four Seasons, Chevrolet, Toyota Prius, Audi, Actuator, Cadillac, NNA, ADAS, Multimedia, Product life-cycle management (marketing), Atmosphere of Earth, F-150, Escalade, Ford Motor Company, Mustang, Accent, Lake Tahoe, Compressor, Jeep Grand Cherokee, Connector, Spark, TLX, Instrumentation, Season

NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) is pleased to announce the addition of 314 new part numbers in its August new number announcement.

Key Points: 
  • NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) is pleased to announce the addition of 314 new part numbers in its August new number announcement.
  • SMP is committed to providing replacement parts for hybrid and electric vehicles through its Standard, Standard Import, and Four Seasons brands.
  • This month's release expands on powertrain-neutral coverage for both Standard and Four Seasons with over 170 new Sensors, Switches, Actuators, and Connectors.
  • With over 100 years in business, Standard Motor Products, Inc. is a leading independent manufacturer and distributor of premium automotive replacement parts.

New Acura ZDX and ZDX Type S Will Take Brand's Precision Crafted Performance into the Electrified Era

Retrieved on: 
금요일, 8월 19, 2022
Acura ZDX, Multimedia, SUV, MDX, Carbon, TLX, Architecture, GM, RDX, EV, NSX, Monterey Car Week, Type S, Integra, Rail transport, Acura

Demonstrating its commitment to performance in the electrified era, Acura will also launch with a ZDX Type S variant, as the brand continues to focus on putting the driver experience first.

Key Points: 
  • Demonstrating its commitment to performance in the electrified era, Acura will also launch with a ZDX Type S variant, as the brand continues to focus on putting the driver experience first.
  • The ZDX will be the first production model to feature many of the styling themes of the new Acura design direction introduced during Monterey Car Week in the form of the Acura Precision EV Concept.
  • The ZDX is being co-developed with GM utilizing the highly flexible global EV platform powered by Ultium batteries.
  • "Acura will remain focused on performance in the electrified era and Type S will continue to represent the pinnacle of this direction."

Acura Precision EV Concept Debuts at Monterey, Previews Future Design Language for Electrified Era

Retrieved on: 
목요일, 8월 18, 2022
Diamond, Multimedia, SUV, MDX, Carbon, Motorsport, Pebble Beach Concours d'Elegance, FSC, TLX, Technology, Quail, Biomass, Wood, Environment, Life, Formula One, Code, Language, Perception, Paul Quail, RDX, NSX, EV, Automation, Water, Forest, Color, Aluminium, Monterey Car Week, HMI, Concept, Type S, Integra, 3D printing, Industrial design, Acura

"The Acura Precision EV Concept is a design study that will shape the direction of future Acura products in the electrified era including our first all-electric SUV in 2024," said Emile Korkor, assistant vice president of Acura National Sales.

Key Points: 
  • "The Acura Precision EV Concept is a design study that will shape the direction of future Acura products in the electrified era including our first all-electric SUV in 2024," said Emile Korkor, assistant vice president of Acura National Sales.
  • "The Acura Precision EV Concept is a look into our future direction and continues Acura's Precision Crafted Performance design language with a modern expression of performance"said Dave Marek, Acura executive creative director.
  • "The Acura Precision EV Concept will be our North Star as we move into an exciting electrified future, and you will see these design cues translate over to future production models."
  • "The Acura Precision EV Concept gives a sneak peek of our future Dual Experience interior design philosophy," said Simon Yu, senior interior designer.

Kevin Richardson appointed as CEO, Telix Americas

Retrieved on: 
일요일, 7월 10, 2022
FDA, LinkedIn, CEO, Moses Austin, Nuclear medicine, TLX, ASX, Marketing, Growth, Degenerative disease, Liver cancer, Company, Boston Scientific, Australian Securities Exchange, MBA, Food, University, MTR, General manager, Head, St. Jude Medical, TGA, Radiopharmaceutical, Regulation of tobacco by the U.S. Food and Drug Administration, Gallium, Management, Pharmaceutical industry, Telix

MELBOURNEand INDIANAPOLIS, July 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)is pleased to announce that Kevin Richardson, a senior global executive with a career focus on sales, marketing and business operations in the oncology and radiopharmaceutical markets, will commence in the role of CEO, Telix Americas, on 11 July 2022.

Key Points: 
  • MELBOURNEand INDIANAPOLIS, July 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)is pleased to announce that Kevin Richardson, a senior global executive with a career focus on sales, marketing and business operations in the oncology and radiopharmaceutical markets, will commence in the role of CEO, Telix Americas, on 11 July 2022.
  • During his tenure, firstly as Head of Sales, and then subsequently in the roles of General Manager and CEO Americas, Kevin oversaw a five-fold increase in sales for the U.S. region.
  • I have confidence that Kevin brings the leadership skills and track record that will drive our growth in the region."
  • Kevin Richardson added, "I'm very excited to take on the role of CEO for Telix Americas.

Telix at EAU 2022, Focus on PSMA-PET Imaging

Retrieved on: 
목요일, 6월 30, 2022
Department, Nuclear medicine, Institute, PSMA, FDA, Patient, LinkedIn, Regulation of tobacco by the U.S. Food and Drug Administration, TLX, 2021 Essex County Council election, EAU, ASX, Degenerative disease, Company, Disease, Australian Securities Exchange, Dana–Farber Cancer Institute, Medical imaging, Kidney, Prostate cancer, Food, Pets United, PET, Medical director, Prostate, MTR, TGA, Congress, Radboud University Nijmegen, Department of Urology, University of Virginia, Gallium, Telix, Urology

[3],[4] The scientific community is now focusing on how PSMA-PET could improve the management of disease, and discussion at EAU will centre around the latest developments in prostate cancer imaging and how PSMA-PET imaging may support improved treatment decisions.

Key Points: 
  • [3],[4] The scientific community is now focusing on how PSMA-PET could improve the management of disease, and discussion at EAU will centre around the latest developments in prostate cancer imaging and how PSMA-PET imaging may support improved treatment decisions.
  • This will be a focus of the Telix-sponsored symposium,The Influence of PSMA on Prostate Cancer Management, being held on Sunday, 3 July, 2022, at 17:45 CET.
  • Telix Chief Medical Officer, Dr Colin Hayward said, "We are excited to be at EAU 2022, showcasing Telix's urologic oncology pipeline across prostate and kidney cancers at the first in-person EAU annual congress since 2019.
  • [6] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[7] and Canada.

Honda Ties for Leading Automaker in Cars.com 2022 American-Made Index with Four Models in Top 10

Retrieved on: 
수요일, 6월 22, 2022
TLX, Marysville Auto Plant, Honda HA-420 HondaJet, Geier v. American Honda Motor Co., GE Honda Aero Engines, View, RDX, MDX, Car, Plant, GE Honda HF120, Ridge, GE, Cars.com, Multimedia, Motor vehicle, Acura, Odyssey

Honda operates five automobile plants in the U.S. more than any other international automaker.

Key Points: 
  • Honda operates five automobile plants in the U.S. more than any other international automaker.
  • Honda vehicles in the top 10 are the Alabama-made Honda Passport SUV,Ridgeline pickup, Odyssey minivan and Pilot SUV.
  • Three Ohio-made Acura models the Acura flagship, fourth generation MDX SUV, RDX premium sport crossover and TLX premium sport sedan placed 14th, 15th and 16th respectively.
  • All four of the Honda models in the top 10 Passport,Ridgeline, Odyssey and Pilot also were designed and developed by Honda engineers in the U.S. and are produced exclusively in Lincoln, Alabama.

Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

Retrieved on: 
월요일, 6월 13, 2022
Australian Securities Exchange, Gallium, Dysplasia, PET, Paget, Company, PSMA, Pharmacy, PSA, Man, Nausea, MTR, Food, LinkedIn, TGA, TLX, Paget's disease, Dizziness, Prostate cancer, Physician, Chief executive officer, Serum, FDA, Patient, Cancer, Risk, Antiandrogen, Radiation, Diarrhea, Control, ADT, Degenerative disease, Plasma protein binding, Disclosure, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymph, Safety, Osteophyte, Medical imaging, Pharmaceutical industry, Animal, Telix

Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.

Key Points: 
  • Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.
  • The expansion of the distribution network facilitates broader patient access to Illuccix across the country, expanding availability into new regional markets that to date have had limited access to PSMA PET imaging.
  • Our goal is to ensure broad access to PSMA PET imaging from the largest metropolitan cities to regional areas and the expansion of the distribution network to include Jubilant Radiopharma puts an Illuccix scan within reach of even more patients in need."
  • "We are pleased to be able to expand our range and service to include Illuccix, and offer our customers the added convenience of PSMA PET imaging with Illuccix," says Renato Leite, President, Jubilant Radiopharmacies Division.

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

Retrieved on: 
금요일, 6월 10, 2022
Australian Securities Exchange, Gallium, Radiation, Dysplasia, Caregiver, PET, Paget, SRS, PSMA, Lymph, PSA, Man, Company, Nausea, MTR, Toxicity, Food, LinkedIn, TGA, Partnership, Cancer, Positron, TLX, IMRT, Paget's disease, Prostate cancer, Dizziness, Osteophyte, Serum, FDA, Patient, Hospital, Risk, Technology, Antiandrogen, Twitter, Diarrhea, Reflection, ADT, Degenerative disease, Plasma protein binding, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Safety, SBRT, Medical imaging, Pharmaceutical industry, Telix, Control

RefleXion is exclusively partnering with Telix for 68Ga PSMA-PET imaging agents for use with BgRT.

Key Points: 
  • RefleXion is exclusively partnering with Telix for 68Ga PSMA-PET imaging agents for use with BgRT.
  • More than 60,000 men undergo external-beam radiotherapy for prostate cancer every year in the U.S. alone[2].
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.You may also report adverse reactions to Telix by calling1-844-455-8638or via email to [email protected] .

Telix Showcasing Innovation in Theranostics at SNMMI

Retrieved on: 
월요일, 6월 6, 2022
Australian Securities Exchange, SNMMI, PET, Seattle Cancer Care Alliance, Company, PSMA, Research, Marketing, MTR, Food, LinkedIn, Detection, TGA, Forward-looking statement, University of Washington, PCA, Gallium, TLX, Prostate cancer, Multimedia, University, Prostate, FDA, Patient, PDT, Industry, Molecular imaging, Scottish Criminal Cases Review Commission, Nuclear medicine, Degenerative disease, ASX, Date-time group, Regulation of tobacco by the U.S. Food and Drug Administration, View, Medical imaging, Pharmaceutical industry, Animal, Telix, Radiology

SNMMI presentation details are as follows:

Key Points: 
  • SNMMI presentation details are as follows:
    Sponsored Symposium: PSMA: the next frontier in Theranostics - transforming PCa care.
  • Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
  • Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.